An interventional study of Transcutaneous vagus nerve stimulation and Closed-loop AM-tACS in Alcohol Dependence, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-03-20.
Sponsored by Charite University, Berlin, Germany · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Alcoholism by Charite University, Berlin, Germany — 4 open to participants now, 4 under way, none of them phase 3. Alcoholism · Charite University, Berlin, Germany.
Among the 14 studies in Alcoholism by Charite University, Berlin, Germany, this one is one of 3 that started in 2024, is one of 5 with no phase, and was the 11th registered.
1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.
Browse Alcoholism studies →4 of the 14 studies in Alcoholism by Charite University, Berlin, Germany are open now, in 1 country. Recruiting first, the newest first:
Charite University, Berlin, Germany · Sites in Germany
Ages 16–65
Charite University, Berlin, Germany · Sites in Germany
Ages 18–65
Charite University, Berlin, Germany · Sites in Germany
Ages 18–65 · Healthy volunteers
By country, each count listing its studies:
Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 1 · Phase 3 2
First in 2007; this study’s year is marked. 3 started in 2024.
This study's planned enrollment of 140 is above the median of 88 across 1,433 interventional studies indexed under Alcoholism.
Median enrollment 80 across the 7 interventional studies, 200 across the 7 observational. Of the 8 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 128 are open to participants now.
3 of the studies in Alcoholism by Charite University, Berlin, Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06308484Charite University, Berlin, GermanyNeuromodulation and Mindfulness Patients With AUD | 2027-06-30 |
| NCT06256952Charite University, Berlin, GermanyEffect of Social Isolation on the Role of Pavlovian Mechanisms for Control Over Alcohol Use | 2027-06-30 |
| NCT07667790Charite University, Berlin, GermanyEffects of Olfactory Stimuli in Virtual Reality Cue Exposure on Craving and Attentional Bias in Alcohol Use Disorder | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 14 studies in Alcoholism by Charite University, Berlin, Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Our primary objective is to integrate tVNS and mindfulness meditation within a structured mindfulness-based relapse prevention (MBRP) program for detoxified alcohol-dependent patients (AD). We aim to determine whether neuromodulation can enhance mindfulness-based relapse prevention compared to mindfulness practice alone. In this context, we will investigate potential changes in the interaction of top-down control and cue reactivity, as well as assess the severity of AUD. Measurements of drinking behavior, cravings, and abstinence rates will be conducted up to three months post-treatment. Our second objective is to examine the causal role of frontal midline theta oscillations (FMΘ) in MBRP and cognitive control. To achieve this, we will first establish closed-loop amplitude-modulated transcranial alternating current stimulation (CLAM-tACS) to selectively modulate FMΘ oscillations during MBRP meditation exercises in AUD patients (2).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The tVNS device consisted of two titan electrodes mounted on a gel frame and connected to a wired neurostimulation device (tVNS Health GmbH, Germany). Electrodes were placed on the cymba conchae. Stimulation intensity of 0.5 mA, delivered with a pulse width of 200-300 μs at 25 Hz.
Device: Transcutaneous vagus nerve stimulation
Stimulation parameters equivalent to active but sham stimulation was administered by positioning the electrodes on the central part of the left earlobe rather than the outer auditory canal, as the earlobe lacks vagus innervation.
Device: Transcutaneous vagus nerve stimulation
We will deliver amplitude-modulated transcranial alternating current stimulation (AM-tACS) using two circular rubber electrodes (4 cm diameter) positioned at the Fpz and Cz locations of the international 10-20 system. The AM-tACS stimulation waveform features a carrier signal frequency of 10 kHz, an amplitude of ±1 mA, and a signal that is real-time synchronized with theta oscillations of the frontal midline. In the active condition target oscillations (frontal midline theta) will be increased.
Device: Closed-loop AM-tACS
Equivalent to the active comparator - except here the target oscillation will be suppressed.
Device: Closed-loop AM-tACS
Patients that are enrolled in a MBRP program will be subjected to weekly tVNS stimulation during a 30-minute audio guided mindfulness exercise.
Patients that are enrolled in a MBRP program will be subjected to weekly CLAM-tACS stimulation during a 30-minute audio guided mindfulness exercise.
Cognitive Control
Before and after the treatment, we will assess cognitive control on a behavioral (response inhibition) and neurophysiological level (electroencephalogram) using a Simon GoNogo task, which reliably triggers activation of the frontal midline regions (Swick et al., 2011).
Time frame: Pre and post intervention after 6-8 weeks
Interoception
Additionally, interoceptive control is intended to be measured using a heartbeat detection task (Kleckner et al., 2015).
Time frame: Pre and post intervention after 6-8 weeks
Cue-Reactivity
Evaluate physiological reactivity to alcohol cues through a passive viewing task developed based on the guidelines of Ekhitiari et al. (2022) and measure subjective cue-induced cravings.
Time frame: Pre and post intervention after 6-8 weeks
Heartrate
Heartrate change due to stimulation
Time frame: pre, ad interim at every tVNS and CLAM-tACS stimulation (once per week for 6-8 weeks), post after 6-8 weeks
Heartrate Variability
Heartrate variability change due to stimulation
Time frame: pre, ad interim at every tVNS and CLAM-tACS stimulation (once per week for 6-8 weeks), post after 6-8 weeks
Mindfulness
Trait and state mindfulness
Time frame: pre, post after 6-8 weeks
Alcohol consumption
Frequency of drinking days and quantity of alcohol consumed
Time frame: pre, post after 6-8 weeks, follow-up three months later
Dependence Severity (Alcohol Dependence Scale)
Craving, urge and dependence severity assessed via questionnaires.
Time frame: pre, post after 6-8 weeks, follow-up three months later
Plan to share: No
Started Mar 2024 (actual). Primary completion is estimated for Jun 2027, 39 months after the start.
Of 472 non-industry interventional studies with no phase under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 54. This study's planned 39 months is above that.
Counting every sponsor, half of 495 studies reached it within 33 months; a quarter within 17 and three quarters within 52.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →